LFB Group
http://www.lfb.fr/en/home.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LFB Group
Coronavirus Update: Searching For A Treatment
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- GTC Biotherapeutics, Inc.
- LFB Biotechnologies, S.A.S.
- rEVO Biologics